Combination Antipsychotic Therapies: An Analysis from a Longitudinal Pragmatic Trial

Adriana Elena Foster, Peter F Buckley, John Lauriello, Stephen Warwick Looney, Nina Schooler

Research output: Contribution to journalArticle

Abstract

Background Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68% patients relapsed versus 53% in the LAI, and 52% in the OA groups. Although there was no significant difference in the relapse rate among groups on χ 2 test (χ 2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ 2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.

Original languageEnglish (US)
Pages (from-to)595-599
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume37
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Pragmatic Clinical Trials
Antipsychotic Agents
Recurrence
Schizophrenia
Therapeutics
Injections
Hospitalization Insurance
Risperidone

Keywords

  • antipsychotic
  • combinations
  • prognosis
  • relapse
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Combination Antipsychotic Therapies : An Analysis from a Longitudinal Pragmatic Trial. / Foster, Adriana Elena; Buckley, Peter F; Lauriello, John; Looney, Stephen Warwick; Schooler, Nina.

In: Journal of Clinical Psychopharmacology, Vol. 37, No. 5, 01.10.2017, p. 595-599.

Research output: Contribution to journalArticle

Foster, Adriana Elena ; Buckley, Peter F ; Lauriello, John ; Looney, Stephen Warwick ; Schooler, Nina. / Combination Antipsychotic Therapies : An Analysis from a Longitudinal Pragmatic Trial. In: Journal of Clinical Psychopharmacology. 2017 ; Vol. 37, No. 5. pp. 595-599.
@article{67d6fd64b8a6464c8c7933dca7fbb1cf,
title = "Combination Antipsychotic Therapies: An Analysis from a Longitudinal Pragmatic Trial",
abstract = "Background Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68{\%} patients relapsed versus 53{\%} in the LAI, and 52{\%} in the OA groups. Although there was no significant difference in the relapse rate among groups on χ 2 test (χ 2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ 2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.",
keywords = "antipsychotic, combinations, prognosis, relapse, schizophrenia",
author = "Foster, {Adriana Elena} and Buckley, {Peter F} and John Lauriello and Looney, {Stephen Warwick} and Nina Schooler",
year = "2017",
month = "10",
day = "1",
doi = "10.1097/JCP.0000000000000766",
language = "English (US)",
volume = "37",
pages = "595--599",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Combination Antipsychotic Therapies

T2 - An Analysis from a Longitudinal Pragmatic Trial

AU - Foster, Adriana Elena

AU - Buckley, Peter F

AU - Lauriello, John

AU - Looney, Stephen Warwick

AU - Schooler, Nina

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68% patients relapsed versus 53% in the LAI, and 52% in the OA groups. Although there was no significant difference in the relapse rate among groups on χ 2 test (χ 2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ 2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.

AB - Background Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68% patients relapsed versus 53% in the LAI, and 52% in the OA groups. Although there was no significant difference in the relapse rate among groups on χ 2 test (χ 2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ 2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.

KW - antipsychotic

KW - combinations

KW - prognosis

KW - relapse

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85032437921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032437921&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000766

DO - 10.1097/JCP.0000000000000766

M3 - Article

C2 - 28806390

AN - SCOPUS:85032437921

VL - 37

SP - 595

EP - 599

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -